COVID-19 Stories

FEB '20


DxD hub, in collaboration with it's partners, responded to the global crisis by developing a test kit that effectively defects the SARS-CoV-2 virus. Having received Provinsional Authorisation for clincal use by Singapore Health Science Authority (HSA), FORTITUDE 2.0 was deployed across hospitals and labs in Singapore and in 45 countries.

Read more


May '20


There was an increasing need for serological tsting to provide epidemiological insights. Conducting a PCR test in conjuction with serological test, we can establish if the infection is an ongoing infection, pas infection or a re-infection.

Read more


JUN '20

Resolute 2.0

DSO proceeded to develop a Direct PCR kit and collaborated with DxD Hub on Resolute 2.0. The lack of resources and RNA extraction kits meant there was growing need for an alternative. Resolute 2.0 addressed that need with a single reagent process.

Read more

JUN' 20


Our parteners worked closely with us to automate and optimise the existing manual process. With the new process in place, RAVE can test up to 6000 samples per day.

Read more



GASTROClear is the world’s first approved microRNA blood test for early detection of gastric cancer offered in ClinLab. It was co-developed with MiRXES, Singapore Gastric Cancer Consortium (SGCC), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).

  • High performance test which detected 87.5% of stage I gastric cancers and 89.5% of stage II gastric cancers in clinical validation.
  • Minimally invasive procedure which requires only 5 millilitres of patient’s blood.
  • An actionable diagnostic test for cancer screening which gives a quantitative risk score and classifies each patient into a risk group.
gastroclear sf-size=

Digital Health

Respiree Monitor

Respiree monitor is a wearable wireless device that monitors COVID-19 patients by predicting worsening conditions. It was co-developed with Respiree and Singapore Bioimaging Consortium (SBIC).

  • Allows for comfortable wearing without sticking to skin.
  • Measures vital signs and trends to provide a risk score, thus predicting health deterioration.


aiTRIAGE™ is a SaMD using (clinical-based) machine learning algorithm to assist clinicians in quickly and accurately triaging patients at risk of Major Adverse Cardiac Event (MACE). It is currently in development with TIIM Healthcare (SGH and NHIC).


  • Co-developed with Genome Institute of Singapore (GIS), this kit is based on loop mediated isothermal amplification (LAMP) technology, which enables rapid amplification and detection of COVID-19. Following licensing to AITBiotech, the abTES COVID-19 has been made commercially available in the market, as well as becoming CE IVD certified. 


  • The INSPECTA is an Automated Reverse Transcription Polymerase Chain Reaction (RT-PCR) Curve Analysis and Test Interpretation system to be used with the RESOLUTE 2.0 Direct PCR Test Kit for SARS-CoV-2 Detection. It has received HSA approval as a Class A SaMD, and has been validated with both Bio-Rad’s CFX qPCR and Applied Biosystems’ QuantStudtio 5 Systems. The INSPECTA has since been made commercially available under a licensing agreement with Alliance Biomed, and has been deployed at a local commercial laboratory. 


  • The REDAPT is a sample collection kit with proprietary chemistry, enabling deep throat saliva (DTS) specimen collection for RESOLUTE 2.0. It is the only test kit approved for use with the RESOLUTE 2.0 test kit. 


  • The TISSUE500 is a pan-cancer assay, enabling Asian-centric molecular characterization of tumours based on Next-Generation Sequencing (NGS) technology. Commercially launched in 2021, the Tissue500 was showcased in both local and international conferences, such as the Frontiers in Cancer Science Conference 2021, and the United States & Canadian Academy of Pathology (USCAP) 2022 Annual Meeting. The test is offered as a Laboratory Developed Test (LDT) by Lucence, with services provided by Lucence's CAP lab in SG, catering to local and regional hospitals.


  • The FxMammo is an AI-assisted algorithm that screens for breast cancer automatically and accurately from digital mammography images. It is one of six innovations (of 256) to receive an award at the Healthcare Innomatch 2022. Using the FxMammo, false positives have been demonstrated to be reduced from 9% to 2%.